Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis

BACKGROUND: Age-related macular degeneration (AMD) is a leading cause of blindness worldwide and is the most common cause of blindness in developed countries. Despite antivascular endothelial growth factor (anti-VEGF) therapy demonstrating improvements in visual and anatomical outcomes, unmet needs...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Justin S, Carlton, Rashad, Agashivala, Neetu, Hassan, Tarek, Wykoff, Charles C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390922/
https://www.ncbi.nlm.nih.gov/pubmed/34057392
http://dx.doi.org/10.18553/jmcp.2021.27.6.743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390922/
https://www.ncbi.nlm.nih.gov/pubmed/34057392
http://dx.doi.org/10.18553/jmcp.2021.27.6.743

Ejemplares similares